10.58
-0.18
(-1.67%)
May 22 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 10.44 - 10.95 |
| 52 week | 6.93 - 12.30 |
| Open | 10.80 |
| Vol / Avg. | 840,494.00/2.25M |
| Mkt cap | 678.13M |
| P/E | - |
| Div/yield | - |
| EPS | -0.86 |
| Shares | 64.10M |
| Beta | 1.25 |
| Inst. own | 67% |
Events
Jul 22, 2013
Q2 2013 EXACT Sciences Corporation Earnings Release
May 21, 2013
EXACT Sciences Corporation at UBS Global Healthcare Conference
May 15, 2013
EXACT Sciences Corporation at Bank of America Merrill Lynch Health Care Conference
May 9, 2013
EXACT Sciences Corporation at Robert W Baird and Co Growth Stock Conference
May 1, 2013
Q1 2013 EXACT Sciences Corporation Earnings Conference Call
May 1, 2013
Q1 2013 EXACT Sciences Corporation Earnings Release
Apr 18, 2013
EXACT Sciences Corporation Conference Call to Discuss Top-Line Results of DeeP-C Clinical Trial
Mar 18, 2013
EXACT Sciences Corporation at Roth Conference
Feb 26, 2013
EXACT Sciences Corporation at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -1047.68% | -1264.98% |
| Operating margin | -1051.83% | -1270.32% |
| EBITD margin | - | -1246.55% |
| Return on average assets | -41.05% | -50.15% |
| Return on average equity | -46.38% | -57.58% |
| Employees | 87 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company�s Cologuard test is a non-invasive, stool-based DNA (sDNA) screening test designed to detect deoxyribonucleic acid (DNA) markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company�s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The target sensitivity rate of its Cologuard test for cancer is equal to or greater than 85% at a specificity of 90%.
Officers and directors
| James P. Connelly | Independent Chairman of the Board | |
| Kevin T. Conroy | President,Chief Executive Officer,Director | |
| Maneesh K. Arora | Chief Financial Officer, Chief Operating Officer | |
| Graham P. Lidgard Ph.D. | Senior Vice President, Chief Scientific Officer | |
| Laura S. Stoltenberg | Chief Commercial Officer | |
| Thomas D. Carey | Director | |
| Sally W. Crawford | Independent Director | |
| Daniel J. Levangie | Independent Director | |
| Katherine S. Napier | Independent Director | |
| Lionel N. Sterling | Independent Director |